Control of the ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will require one or more vaccines . Currently, numerous SARS-CoV-2 vaccines are in either pre-clinical or clinical development . Twenty are in fase III development . In this review we summarise available safety and efficacy data of two RNA based vaccines, two non-replication competent vector-based vaccine, one inactivated whole-virus vaccine, and one subunit . All being either approved or nearing approval.